Operator: Good day, and welcome to the Delcath Systems Reports Third Quarter Fiscal Year 2023 Financial Results. All participants will be in listen-only mode.
A research team co-led by UCLA investigators has shown that an immunotherapy drug combination can be an effective second-line therapy for patients with an aggressive and deadly type of melanoma that is resistant to the widely used immunotherapy drugs known as PD-1 inhibitors.
SAN CARLOS, Calif., April 26, 2023 Atreca, Inc. , a clinical-stage biotechnology company focused on developing novel cancer therapeutics generated through a unique discovery platform based on. | April 26, 2023